Helen M. Thackray, M.D., serves as the Chief R&D Officer at BioCryst Pharmaceuticals Inc., a position she has held since joining the company in 2017. Dr. Thackray is a seasoned medical professional with a robust background in clinical development and medical affairs. She earned her medical degree from the University of Pennsylvania School of Medicine and completed her residency in internal medicine at Massachusetts General Hospital. Her career spans over two decades, during which she has held pivotal roles at several leading pharmaceutical companies, including Vertex Pharmaceuticals and Shire, where she was instrumental in advancing treatments for rare diseases and genetic disorders. At BioCryst Pharmaceuticals, Dr. Thackray leads the company's research and development efforts, focusing on innovative therapies for rare diseases. Under her leadership, BioCryst has made significant strides in the development of ORLADEYO® (berotralstat), an oral therapy for the prevention of hereditary angioedema (HAE) attacks, which received FDA approval in 2020. Her strategic vision and dedication to patient care have been crucial in driving the company's pipeline forward, ensuring that BioCryst remains at the forefront of developing life-changing treatments. Dr. Thackray's contributions have not only advanced the company's scientific goals but have also solidified its reputation as a leader in the rare disease space. In addition to her corporate responsibilities, Dr. Thackray is an active member of the medical community, frequently contributing to scientific literature and participating in industry conferences. Her commitment to advancing medical knowledge and improving patient outcomes is evident in her ongoing engagement with healthcare professionals and patient advocacy groups. Dr. Thackray's leadership at BioCryst Pharmaceuticals exemplifies her passion for innovation and her unwavering dedication to making a meaningful impact on the lives of those affected by rare diseases.